VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma

被引:19
作者
Wrobel, Tomasz [1 ]
Mazur, Grzegorz [2 ]
Dzietczenia, Justyna [1 ]
Gebura, Katarzyna [3 ]
Kuliczkowski, Kazimierz [1 ]
Bogunia-Kubik, Katarzyna [3 ]
机构
[1] Wroclaw Med Univ, Dept Haematol Blood Neoplasms & Bone Marrow Trans, PL-50367 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Internal Occupat Dis & Hypertens, PL-50556 Wroclaw, Poland
[3] Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Lab Clin Immunogenet & Pharmacogenet, PL-53114 Wroclaw, Poland
关键词
ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; PROMOTER REGION; PROGNOSTIC-SIGNIFICANCE; EXPRESSION; RECEPTORS;
D O I
10.1155/2013/159813
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Angiogenesis and lymphangiogenesis are important in the proliferation and survival of the malignant hematopoietic neoplasms, including non-Hodgkin's lymphomas (NHLs). Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play an important role in the initiation of angiogenesis. Both VEGF and bFGF have been reported to have prognostic significance in NHL. The present study aimed to determine an association between the VEGF and bFGF gene polymorphisms and disease susceptibility and progression. VEGF (rs3025039; 936 C>T) and bFGF (rs308395, -921 G>C) variants were determined in 78 NHL patients and 122 healthy individuals by PCR-RFLP technique. The presence of the VEGF 936T allele was found to significantly associate with worse prognosis of the disease (expressed by the highest International Prognostic Index (IPI)) (0.41 versus 0.20, P = 0.044 for IPI 4 among patients having and lacking the T allele). The VEGF 936T variant was also more frequent among patients with IPI 4 than in controls (OR = 3.37, P = 0.029). The bFGF -921G variant was more frequently detected among patients with aggressive as compared to those with indolent histological subtype (0.37 versus 0.18, P = 0.095) and healthy individuals (0.37 versus 0.19, OR = 2.51, P = 0.038). These results imply that VEGF and bFGF gene polymorphisms have prognostic significance in patients with NHL.
引用
收藏
页数:6
相关论文
共 28 条
[1]   A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes [J].
Awata, T ;
Inoue, K ;
Kurihara, S ;
Ohkubo, T ;
Watanabe, M ;
Inukai, K ;
Inoue, I ;
Katayama, S .
DIABETES, 2002, 51 (05) :1635-1639
[2]   Genetic variation in the promoter region of the basic fibroblast growth factor gene [J].
Beránek, M ;
Tschöplová, S ;
Kanková, K ;
Kuhrová, V ;
Vácha, J .
HUMAN IMMUNOLOGY, 2003, 64 (03) :374-377
[3]   Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma [J].
Bogunia-Kubik, K. ;
Mazur, G. ;
Wrobel, T. ;
Kuliczkowski, K. ;
Lange, A. .
TISSUE ANTIGENS, 2008, 71 (02) :146-150
[4]   Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene [J].
Brogan, IJ ;
Khan, N ;
Isaac, K ;
Hutchinson, JA ;
Pravica, V ;
Hutchinson, IV .
HUMAN IMMUNOLOGY, 1999, 60 (12) :1245-1249
[5]   Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma [J].
Diao, Lan-Ping ;
Yu, Xiao-Ming ;
Gao, Yu-Huan ;
Li, Yan ;
Liu, Hai-Sheng ;
Liu, Li-Hong ;
Zhou, Rong-Miao ;
Wang, Na ;
Wu, Li-Li ;
Wang, Shi-Jie .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (11) :1473-1481
[6]   Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma [J].
Galimberti, S. ;
Nagy, B. ;
Palumbo, G. A. ;
Ciancia, E. ;
Buda, G. ;
Orciuolo, E. ;
Melosi, A. ;
Lambelet, P. ;
Ronca, F. ;
Petrini, M. .
ACTA HAEMATOLOGICA, 2010, 123 (02) :91-95
[7]   Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma [J].
Giles, FJ ;
Vose, JM ;
Do, KA ;
Johnson, MM ;
Manshouri, T ;
Bociek, G ;
Bierman, PJ ;
O'Brien, SM ;
Kantarjian, HM ;
Armitage, JO ;
Albitar, M .
LEUKEMIA RESEARCH, 2004, 28 (06) :595-604
[8]   Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma [J].
Hazar, B ;
Paydas, S ;
Zorludemir, S ;
Sahin, B ;
Tuncer, I .
LEUKEMIA & LYMPHOMA, 2003, 44 (12) :2089-2093
[9]   Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma [J].
Ho, CL ;
Sheu, LF ;
Li, CY .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2002, 10 (04) :316-321
[10]   Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas [J].
Jorgensen, Judit M. ;
Sorensen, Flemming B. ;
Bendix, Knud ;
Nielsen, Johan L. ;
Funder, Anette ;
Karkkainen, Marika J. ;
Tainola, Tapio ;
Sorensen, Annette B. ;
Pedersen, Finn S. ;
D'Amore, Francesco .
LEUKEMIA & LYMPHOMA, 2009, 50 (10) :1647-1660